Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
200mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Vfend (voriconazole) is a medication used to treat adults and pediatric patients two years of age or older who have certain fungal infections.
Fact Table | |
Formula |
C16H14F3N5O |
License |
US DailyMed, EU EMA, US FDA |
Bioavailability |
96% |
Legal status |
Rx-only |
Chemical Name |
Voriconazole |
Elimination half-life |
Dose-dependent |
Dosage (Strength) |
50mg |
Pregnancy |
Not Recommended |
Brands |
Vfend |
Protein binding |
58% |
PubChem CID |
71616 |
MedlinePlus |
a605022 |
ChEBI |
10023 |
ATC code |
J02AC03 |
DrugBank |
DB00582 |
KEGG |
D00578 |
Routes of administration |
By mouth |
Follow the instructions that come with your prescription. If you have any questions or concerns, don't hesitate to reach out to your doctor or pharmacist.
Vfend comes in tablets of 50 mg and 200 mg strengths. It's also available in a 40 mg/mL oral suspension.
Maintenance Dose in Adults Weighing 40 kg or More |
200 mg by mouth every 12 hours |
Maintenance Dose in Adults Weighing Less Than 40 kg |
100 mg or 150 mg by mouth every 12 hours |
Maintenance Dose in Pediatric Patients Who are 2 to 11 Years of Age |
9 mg per kg by mouth every 12 hours (maximum 350 mg every 12 hours) |
Maintenance Dose in Pediatric Patients Who 12 to 14 Years of Age and Weigh Less Than 50 kg |
9 mg per kg by mouth every 12 hours (maximum 350 mg every 12 hours) |
Maintenance Dose in Pediatric Patients Who are 12 to 14 Years of Age and Weigh 50 kg or More |
Use adult dose |
Maintenance Dose in Pediatric Patients Who are 15 Years of Age and Older |
Use adult dose |
The dose may require an adjustment in adults who have liver or kidney issues.
Vfend tablets and oral suspension should be stored at room temperature. Throw away the suspension after 14 days.
Shake the suspension for about 10 seconds before each use. Use the dropper that comes with your prescription.
The active ingredient in Vfend is voriconazole.
The inactive ingredients in Vfend tablets include croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone, pregelatinized starch, and a coating containing hypromellose, lactose monohydrate, titanium dioxide, and triacetin.
The inactive ingredients in the Vfend oral suspension include anhydrous citric acid, colloidal silicon dioxide, natural orange flavor, sodium benzoate, sodium citrate dihydrate, sucrose, titanium dioxide, and xanthan gum.
Avoid taking Vfend if you have an allergy to voriconazole or any of the other ingredients or excipients in Vfend.
Avoid taking Vfend with pimozide, quinidine, sirolimus, or ivabradine as drug interactions may occur and lead to serious reactions. If you do not know if you are taking any of these medications, ask your doctor.
Avoid taking Vfend with rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. John's Wort as this may cause the medication to be less effective. If you do not know if you are taking any of these medications, ask your doctor.
Avoid taking Vfend with naloxegol, tolvaptan, and lurasidone as drug interactions may occur and lead to serious reactions. If you do not know if you are taking any of these medications, ask your doctor.
Avoid taking Vfend with venetoclax at the start of and during the ramp up phase in patients who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Drug interactions may occur and lead to serious reactions. If you do not know if you are taking venetoclax, ask your doctor.
In adult patients, the most common side effects reported include vision problems, fever, nausea, rash, vomiting, chills, headache, abnormal liver function tests, rapid heart rate, and hallucinations.
In pediatric patients, the most common side effects reported include vision problems, fever, vomiting, nosebleeds, nausea, rash, stomach pain, diarrhea, high blood pressure, low potassium levels in the blood, cough, headache, low platelet levels, abnormal ALT, low blood pressure, peripheral edema, high blood glucose levels, rapid heart rate, shortness of breath, low calcium levels in the blood, low phosphorus levels in the blood, abnormal LFT, mucosal inflammation, eye discomfort in the presence of bright lights, abdominal distention, constipation, dizziness, hallucinations, coughing up blood, low albumin levels, low magnesium levels in the blood, kidney problems, and upper respiratory tract infection.
If side effects develop that continue or worry you, inform your doctor right away.
Vfend (voriconazole). New York, NY: Pfizer, Inc.; 2022.